Business Wire

MI-EATON

16.11.2021 12:32:13 CET | Business Wire | Press release

Share
Eaton Leverages Cylinder Deactivation and Exhaust Thermal Management Technologies to Reduce Commercial Vehicle Emissions

Power management company Eaton today announced its Vehicle Group has demonstrated cylinder deactivation (CDA) as an effective technology for meeting future global emissions requirements for diesel-engine powered commercial vehicles. To date, the technology has been evaluated with a close-coupled selective catalytic reduction (SCR) aftertreatment system with and without a 48-volt electric heater.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005234/en/

“Our CDA technology has proven it can help our customers meet increasingly strict emissions regulations for diesel engines,” said Christopher Mancuso, business unit director, Engine Air Management, Eaton’s Vehicle Group. “This comes at a time when many global manufacturers are determining what technologies they will leverage in next-generation vehicles to reduce harmful emissions.”

New emissions regulations spearheaded by the California Air Resources Board (CARB), U.S. Environmental Protection Agency (EPA) and European Commission (EC) are slated for adoption in coming years. These agencies, in concert with other national and international regulators, seek to significantly reduce greenhouse gas (GHG) emissions and harmful air pollutants produced primarily by heavy-duty trucks, vans and buses.

Rapid catalyst warm-up essential

Eaton partnered with the Southwest Research Institute (SwRI), one of the oldest and largest independent, nonprofit, applied research and development organizations in the U.S., to demonstrate the feasibility of its Vehicle Group’s technology. The findings demonstrate that using CDA and a close-coupled SCR catalyst reduced both nitrous oxide (NOx) and carbon dioxide (CO2 ) emissions with fuel consumption savings of up to 40% at idle.

Previous results utilizing CDA and a close-coupled SCR catalyst demonstrated compliance to forthcoming U.S. regulations for NOx and CO2 emissions for diesel commercial vehicles. Testing with the new low-load cycle (LLC) resulted in a 5% drop in CO2 while dramatically reducing NOx. The assessment was developed by CARB to replicate real-world urban tractor and vocational vehicle operations at low engine loads.

Eaton’s 2021 testing with SwRI showed further advancement, dropping NOx levels by 99.4% on the composite federal test procedure (FTP) and lowering the LLC NOx to well within current guidelines. Notably, using the same aftertreatment system with the addition of a 48-volt electric heater located upstream of the SCR further achieved a reduction in CO2 .

CDA technology can benefit vehicle manufacturers facing tightening emissions standards in Europe as well. The next set of requirements, known as Euro VII for heavy-duty trucks, is targeted for the second part of the decade. In the U.S., CARB is introducing more stringent regulations as soon as 2024, while the EPA has circled 2027 to begin applying stricter emissions limits on new-model heavy-duty vehicles. Collectively, these standards are designed to reduce tailpipe NOx emissions up to 90%, accelerating the need for global engine manufacturers to employ additional emissions-reduction strategies such as electric catalyst heating. This technology is an example of how Eaton is progressing toward achieving its 2030 Sustainability Targets . By 2030, the company aims to reduce emissions from its solutions and throughout its value chain by 15%.

Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye